Highlights Edesa Biotech, Inc.

Equities

EDSA

CA27966L3065

Delayed Nasdaq Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
4.452 ^USD	+0.21%		+3.30%	-2.57%

Mar. 05	Top Premarket Gainers	MT
Feb. 09	Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 09	CI
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 15	CI
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	Nov. 20	CI
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	23-10-25	CI
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	23-10-12	CI
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	23-10-10	MT
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	23-09-28	CI
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-09	CI
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	23-06-28	CI
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-11	CI
Edesa Biotech, Inc. to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	23-03-16	CI
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study	23-03-15	CI
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-10	CI
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study	23-02-01	CI
Edesa Biotech, Inc. Reports Topline Phase 2B Results for Dermatology Drug	23-01-17	CI
Edesa Biotech Secures Fast-Track Designation for Potential Acute Respiratory Distress Syndrome Drug Candidate	22-12-20	MT
Fda Grants Fast Track to Edesa Biotech's Ards Drug Candidate	22-12-20	CI
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-16	CI
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-16	CI
Edesa Shares Rise After Trial Results Show Antibody Drug Led to 'Significant' Risk Reduction in Hospitalized COVID Patients	22-09-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Edesa Biotech, Inc.

Equities

EDSA

CA27966L3065

Highlights

Filters